血清α-L-岩藻糖苷酶活性在新型冠状病毒感染中的临床相关性

Clinical relevance of serum α-l-fucosidase activity in the SARS-CoV-2 infection.

作者信息

Liang En-Yu, Li Guo-Hua, Wang Wen-Gong, Qiu Xin-Min, Ke Pei-Feng, He Min, Huang Xian-Zhang

机构信息

Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.

Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China; Hubei Integrated Traditional Chinese and Western Medicine Hospital, Wuhan 430015, China.

出版信息

Clin Chim Acta. 2021 Aug;519:26-31. doi: 10.1016/j.cca.2021.03.031. Epub 2021 Apr 5.

DOI:10.1016/j.cca.2021.03.031

PMID:33826953

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8019593/

Abstract

BACKGROUND AND AIMS

The reduced fucosylation in the spike glycoprotein of SARS-CoV-2 and the IgG antibody has been observed in COVID-19. However, the clinical relevance of α-l-fucosidase, the enzyme for defucosylation has not been discovered.

MATERIALS AND METHODS

585 COVID-19 patients were included to analyze the correlations of α-l-fucosidase activity with the nucleic acid test, IgM/IgG, comorbidities, and disease progression.

RESULTS

Among the COVID-19 patients, 5.75% were double-negative for nucleic acid and antibodies. All of them had increased α-l-fucosidase, while only one had abnormal serum amyloid A (SAA) and C-reactive protein (CRP). The abnormal rate of α-l-fucosidase was 81.82% before the presence of IgM, 100% in the presence of IgM, and 66.2% in the presence of IgG. 73.42% of patients with glucometabolic disorders had increased α-l-fucosidase activity and had the highest mortality of 6.33%. The increased α-l-fucosidase was observed in 55.8% of non-severe cases and 72.9% of severe cases, with an odds ratio of 2.118. The α-l-fucosidase mRNA was irrelevant to its serum activity.

CONCLUSION

The change in α-l-fucosidase activity in COVID-19 preceded the IgM and SAA and showed a preferable relation with glucometabolic disorders, which may be conducive to virus invasion or invoke an immune response against SARS-CoV-2.

摘要

背景与目的

在新型冠状病毒肺炎（COVID-19）中已观察到严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突糖蛋白和免疫球蛋白G（IgG）抗体中岩藻糖基化减少。然而，去岩藻糖基化酶α-L-岩藻糖苷酶的临床相关性尚未被发现。

材料与方法

纳入585例COVID-19患者，分析α-L-岩藻糖苷酶活性与核酸检测、IgM/IgG、合并症及疾病进展的相关性。

结果

在COVID-19患者中，5.75%的患者核酸和抗体均为双阴性。他们的α-L-岩藻糖苷酶均升高，而只有1例血清淀粉样蛋白A（SAA）和C反应蛋白（CRP）异常。在IgM出现之前，α-L-岩藻糖苷酶的异常率为81.82%，在IgM存在时为100%，在IgG存在时为66.2%。73.42%的糖代谢紊乱患者α-L-岩藻糖苷酶活性升高，死亡率最高，为6.33%。55.8%的非重症病例和72.9%的重症病例中观察到α-L-岩藻糖苷酶升高，比值比为2.118。α-L-岩藻糖苷酶mRNA与其血清活性无关。